Literature DB >> 20070867

Antipsychotic-induced gene regulation in multiple brain regions.

Matthew James Girgenti1, Laura K Nisenbaum, Franklin Bymaster, Rosemarie Terwilliger, Ronald S Duman, Samuel Sathyanesan Newton.   

Abstract

The molecular mechanism of action of antipsychotic drugs is not well understood. Their complex receptor affinity profiles indicate that their action could extend beyond dopamine receptor blockade. Single gene expression studies and high-throughput gene profiling have shown the induction of genes from several molecular classes and functional categories. Using a focused microarray approach, we investigated gene regulation in rat striatum, frontal cortex, and hippocampus after chronic administration of haloperidol or olanzapine. Regulated genes were validated by in situ hybridization, real-time PCR, and immunohistochemistry. Only limited overlap was observed in genes regulated by haloperidol and olanzapine. Both drugs elicited maximal gene regulation in the striatum and least in the hippocampus. Striatal gene induction by haloperidol was predominantly in neurotransmitter signaling, G-protein coupled receptors, and transcription factors. Olanzapine prominently induced retinoic acid and trophic factor signaling genes in the frontal cortex. The data also revealed the induction of several genes that could be targeted in future drug development efforts. The study uncovered the induction of several novel genes, including somatostatin receptors and metabotropic glutamate receptors. The results demonstrating the regulation of multiple receptors and transcription factors suggests that both typical and atypical antipsychotics could possess a complex molecular mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20070867      PMCID: PMC2921913          DOI: 10.1111/j.1471-4159.2010.06585.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  58 in total

1.  cDNA array reveals differential gene expression following chronic neuroleptic administration: implications of synapsin II in haloperidol treatment.

Authors:  Victor Z Chong; L Trevor Young; Ram K Mishra
Journal:  J Neurochem       Date:  2002-09       Impact factor: 5.372

2.  D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment.

Authors:  M Laruelle; G E Jaskiw; B K Lipska; B Kolachana; M F Casanova; J E Kleinman; D R Weinberger
Journal:  Brain Res       Date:  1992-03-13       Impact factor: 3.252

Review 3.  Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation.

Authors:  Daniel Lévesque; Claude Rouillard
Journal:  Trends Neurosci       Date:  2006-11-28       Impact factor: 13.837

4.  Synapsin II knockout mice show sensorimotor gating and behavioural abnormalities similar to those in the phencyclidine-induced preclinical animal model of schizophrenia.

Authors:  Bailee A Dyck; Kevin J Skoblenick; Jessica M Castellano; Kitty Ki; Nancy Thomas; Ram K Mishra
Journal:  Schizophr Res       Date:  2007-09-27       Impact factor: 4.939

Review 5.  Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway.

Authors:  R R Girgis; J A Javitch; J A Lieberman
Journal:  Mol Psychiatry       Date:  2008-04-15       Impact factor: 15.992

Review 6.  The dopamine transporter and attention-deficit/hyperactivity disorder.

Authors:  Bertha K Madras; Gregory M Miller; Alan J Fischman
Journal:  Biol Psychiatry       Date:  2005-01-05       Impact factor: 13.382

Review 7.  Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression.

Authors:  Husseini K Manji; Jorge A Quiroz; Jonathan Sporn; Jennifer L Payne; Kirk Denicoff; Neil A Gray; Carlos A Zarate; Dennis S Charney
Journal:  Biol Psychiatry       Date:  2003-04-15       Impact factor: 13.382

8.  A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.

Authors:  Gene G Kinney; Julie A O'Brien; Wei Lemaire; Maryann Burno; Denise J Bickel; Michelle K Clements; Tsing-Bau Chen; David D Wisnoski; Craig W Lindsley; Philip R Tiller; Sheri Smith; Marlene A Jacobson; Cyrille Sur; Mark E Duggan; Douglas J Pettibone; P Jeffrey Conn; David L Williams
Journal:  J Pharmacol Exp Ther       Date:  2004-12-17       Impact factor: 4.030

9.  The transcription factors Nur77 and retinoid X receptors participate in amphetamine-induced locomotor activities.

Authors:  Emmanuelle Bourhis; Jérôme Maheux; Brigitte Paquet; Hiroyuki Kagechika; Koichi Shudo; Pierre-Paul Rompré; Claude Rouillard; Daniel Lévesque
Journal:  Psychopharmacology (Berl)       Date:  2008-10-09       Impact factor: 4.530

10.  The transcription factor NGFI-B (Nur77) and retinoids play a critical role in acute neuroleptic-induced extrapyramidal effect and striatal neuropeptide gene expression.

Authors:  Isabelle Ethier; Geneviève Beaudry; Michel St-Hilaire; Jeff Milbrandt; Claude Rouillard; Daniel Lévesque
Journal:  Neuropsychopharmacology       Date:  2004-02       Impact factor: 7.853

View more
  10 in total

1.  Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia.

Authors:  Jeffrey R Bishop; Del D Miller; Vicki L Ellingrod; Timothy Holman
Journal:  Hum Psychopharmacol       Date:  2011-01       Impact factor: 1.672

Review 2.  Epigenetics and biomarkers in the staging of neuropsychiatric disorders.

Authors:  Trevor Archer; Richard J Beninger; Tomas Palomo; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

3.  NeuN+ neuronal nuclei in non-human primate prefrontal cortex and subcortical white matter after clozapine exposure.

Authors:  Tobias B Halene; Alexey Kozlenkov; Yan Jiang; Amanda C Mitchell; Behnam Javidfar; Aslihan Dincer; Royce Park; Jennifer Wiseman; Paula L Croxson; Eustathia Lela Giannaris; Patrick R Hof; Panos Roussos; Stella Dracheva; Scott E Hemby; Schahram Akbarian
Journal:  Schizophr Res       Date:  2016-01-06       Impact factor: 4.939

4.  The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications.

Authors:  N C Carty; J Xu; P Kurup; J Brouillette; S M Goebel-Goody; D R Austin; P Yuan; G Chen; P R Correa; V Haroutunian; C Pittenger; P J Lombroso
Journal:  Transl Psychiatry       Date:  2012-07-10       Impact factor: 6.222

5.  Transcriptomic analysis in a Drosophila model identifies previously implicated and novel pathways in the therapeutic mechanism in neuropsychiatric disorders.

Authors:  Priyanka Singh; Farhan Mohammad; Abhay Sharma
Journal:  Front Neurosci       Date:  2011-03-31       Impact factor: 4.677

6.  Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer's disease.

Authors:  Jeremy Koppel; Heidy Jimenez; Leslie Adrien; Blaine S Greenwald; Philippe Marambaud; Ezra Cinamon; Peter Davies
Journal:  Alzheimers Dement (N Y)       Date:  2016-06-21

7.  Proteomic study revealed antipsychotics-induced nuclear protein regulations in B35 cells are similar to the regulations in C6 cells and rat cortex.

Authors:  Tinchou Li; Mingcheng Lee; Fuming Tsai; Yunhsiang Chen; Yiyin Lin; Maoliang Chen
Journal:  BMC Pharmacol Toxicol       Date:  2018-03-07       Impact factor: 2.483

8.  Gene-microRNA interactions associated with antipsychotic mechanisms and the metabolic side effects of olanzapine.

Authors:  Danielle M Santarelli; Bing Liu; Carlotta E Duncan; Natalie J Beveridge; Paul A Tooney; Peter R Schofield; Murray J Cairns
Journal:  Psychopharmacology (Berl)       Date:  2013-01-15       Impact factor: 4.530

9.  Leukocyte Gene Expression in Patients with Medication Refractory Depression before and after Treatment with ECT or Isoflurane Anesthesia: A Pilot Study.

Authors:  E Iacob; S C Tadler; K C Light; H R Weeks; K W Smith; A T White; R W Hughen; T A VanHaitsma; L A Bushnell; A R Light
Journal:  Depress Res Treat       Date:  2014-04-13

10.  Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [¹¹C]MP-10 PET rodent imaging study with ex vivo confirmation.

Authors:  S Natesan; S Ashworth; J Nielsen; S-P Tang; C Salinas; S Kealey; J B Lauridsen; T B Stensbøl; R N Gunn; E A Rabiner; S Kapur
Journal:  Transl Psychiatry       Date:  2014-04-01       Impact factor: 6.222

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.